Has Alexis Weaver received payments from drug or device companies?

Yes. Drug and device makers reported $426 in general payments to Alexis Weaver across 22 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alexis Weaver did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alexis Weaver come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alexis Weaver

Psychiatric/Mental Health · Morris, ILNPI 1134841455

Payments from drug & device makers

$426in general payments, 2019–2025

Across 22 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$130
Johnson & Johnson$84
Otsuka America Pharmaceutical, Inc.$64
Axsome Therapeutics, Inc.$56
Alkermes, Inc.$32
Ironshore Pharmaceuticals Inc.$24
plus $37 from 2 others

What the payments were for

Food & beverage$426100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	7	$130
Johnson & Johnson	4	$84
Otsuka America Pharmaceutical, Inc.	3	$64
Axsome Therapeutics, Inc.	3	$56
Alkermes, Inc.	2	$32
Ironshore Pharmaceuticals Inc.	1	$24
Supernus Pharmaceuticals, Inc.	1	$20
Vanda Pharmaceuticals Inc.	1	$17

How this compares

$426 in reported general payments places this provider in the 45th percentile of 922 psychiatric/mental health providers in Illinois.

See all psychiatric/mental health providers in Illinois →

Medicare billing

Part B allowed, 2024

$3,769

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Aripiprazole	11	$358
Escitalopram Oxalate	13	$320
Hydroxyzine Hcl	12	$286
Trazodone Hcl	26	$214
Sertraline Hcl	14	$63

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Morris

Erin PetrusicChicago$517K
Maurice BrownleeChicago$162K
Melissa VitaleChicago$151K
Alan AmbergChicago$119K
Jaime MendozaMaryville$111K
Jennifer TheryMaryville$83K
Carole Weddington HuntGranite City$67K
Jessica WhelanBloomington$55K
Lynn LochnerKankakee$41K
Julie CarbrayChicago$36K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →